Drug Sponsors

F2G completes $30M financing round for anti-fungal compounds

Thursday, September 6, 2012 07:48 AM

F2G, an antifungal drug discovery and development company based in Manchester, U.K., has completed a $30 million equity financing round, which will be used to select a clinical candidate from the F3 series of advanced preclinical analogs and proceed to first in man studies.

More... »

Cellerant awarded $36.4M to develop CLT-008 for acute radiation syndrome

Thursday, September 6, 2012 07:48 AM

Cellerant Therapeutics, a biotech developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, has been awarded $36.4 million under an option exercised by the Biomedical Advanced Research and Development Authority (BARDA) in the office of the assistant secretary for preparedness and response of the Department of Health and Human Services, for the advanced development of CLT-008, a first-in-class, allogeneic, cell-based therapy for the treatment of acute radiation syndrome (ARS).

More... »

Survey: Product protection rises as a top supply chain concern among healthcare execs

Wednesday, September 5, 2012 02:22 PM

Healthcare executives around the world are investing in their supply chains as they prepare for continued global growth in an increasingly complex and dynamic environment, according to data from the fifth annual UPS "Pain in the (Supply) Chain" healthcare survey, conducted by TNS.

More... »

Merck, employee representatives agree on efficiency plan for Germany

Wednesday, September 5, 2012 10:47 AM

Merck, a global healthcare company based in Darmstadt, Germany, has signed an agreement with employee representatives on an efficiency plan for the company's Germany operations.

More... »

GE Healthcare launches modular biopharmaceutical factory, KUBio

Wednesday, September 5, 2012 10:26 AM

GE Healthcare, the healthcare business of GE, has launched KUBio, an innovative off-the-shelf, modular factory designed to save manufacturers of biopharmaceuticals both time and money.

More... »

Galapagos subsidiary BioFocus collaborates with Ono on CNS drug discovery

Tuesday, September 4, 2012 12:46 PM

Galapagos’ service division BioFocus and Ono Pharmaceutical have signed a new collaboration agreement focused on discovering novel drugs for CNS disorders. BioFocus will use its drug discovery platform to deliver leads and clinical candidates.

More... »

Merck Serono spin-off Quartz Bio to offer biomarker data analysis

Tuesday, September 4, 2012 12:41 PM

Merck Serono, a division of Merck, has created Quartz Bio, the second spin-off company resulting from its Entrepreneur Partnership Program launched in April. Quartz Bio will offer biomarker data management and exploratory biomarker analysis services to the pharmaceutical industry. Biomarker analysis is a critical step in the drug development process, as it enables the identification of patient profiles most responsive to a given treatment.

More... »

Allergan opens NJ facility

Tuesday, September 4, 2012 12:39 PM

Irvine, Calif.-based Allergan has opened its first large facility in New Jersey, the R&D Center in Bridgewater, N.J.

More... »

Valeant to acquire Medicis, strengthen dermatology offerings

Tuesday, September 4, 2012 12:36 PM

Montreal-based Valeant Pharmaceuticals International and Medicis Pharmaceutical of Scottsdale, Ariz., have entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Medicis for $44 per share in cash. The transaction, which values Medicis' common stock at approximately $2.6 billion, was unanimously approved by the boards of both companies. The $44 price represents a 39% premium to Medicis' closing share price Friday, Aug. 31, the last trading day prior to the announcement, and a 31% premium to the three-month average trading price. The transaction is expected to close in the first half of 2013.

More... »

U.K. general public has fundamental misunderstanding of cost and value of medicines

Monday, September 3, 2012 08:00 AM

A new survey commissioned by the ABPI, has revealed that the British public misunderstands the cost and value of medicines in the U.K.

More... »